



investigadores predoctorales en Investigaciones Biomédicas de Aragón

Welcome to the iplBA seminar series 2022

Short informal talks given by **young researches of Aragón** with the aim to promote 2 main goals:

1. **Networking** between young researchers of Aragón.
2. Improve our **communication skills**.

“Study of the efficacy of intravenous BCG to subvert tumor-induced myelopoiesis alterations and the impact on lung cancer.”

Tuesday, March 8th 2022

From 9:30 to 10:30

Summary:

BCG is a live attenuated mycobacterium and it is at present the only tuberculosis vaccine used in humans. Since more than four decades ago, intravesical BCG represents a gold standard therapy for high-risk non-muscular invasive bladder cancer. Recently, it was reported that BCG can trigger bone marrow (BM) myelopoiesis when delivered by intravenous (i.v.) route, in a process dependant on IFN γ . Presence of BCG at BM drives profound changes in myelopoiesis, with an increase of the frequency of mylopoietic progenitors expressing high levels of certain genes with a well-known tumor-suppressive capacity, as STAT1. The overall objective of this project aims to develop a multifaceted strategy to impair and subvert tumor associated micro- and macro- environments in lung cancer animal models, by the delivery of live attenuated mycobacterial vaccines through systemic routes of administration.

Speaker: Claudia Guerrero Perales (claudia@unizar.es)

Doctoral Programme: Biochemistry, and Molecular and Cellular Biology

Affiliation: Grupo de Genética de Micobacterias, Faculty of Medicine, UNIZAR

Principal Investigator: Carlos Martín

Organizes: iplBA and Institute for Health Research Aragón



Link to join the seminar:

<https://us02web.zoom.us/meeting/register/tZEsfu-hrjsoHdyrGxM247T3dfmqjjqdRrs7>

CIBA, main meeting room, and online via zoom

Tuesday, March 8th 2022 From 9:30 to 10:30

formacion@iisaragon.es • 976 71 38 56